We are interested in how other organizations handle the CMS/TJC/CIHQ requirement that "processes and mechanisms should e established to monitor patient responses to a newly added medication before the medication is made available for dispensing or administration within the hospital."
Do you have a blanket statement in policy that is applicable to every new drug, or do you define individual parameters for each new drug? If you would be willing to share policies that would be very helpful.